ClinicalTrials.gg
CompletedNCT00625365Updated Nov 24, 2020Results posted

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

A Phase 4 interventional study of DEFINITY® in Cardiovascular Disease, sponsored by Lantheus Medical Imaging. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,060
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this registry study is to gather safety information on the current clinical use of and the safety of DEFINITY®

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • DEFINITY
  • Safety
  • Survelliance
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 1,060 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Lantheus Medical Imaging is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who, in the investigator's opinion, require DEFINITY® echocardiography due to suboptimal, unenhanced images.

Exclusion criteria

Exclusion criteria

  • Known to perflutren, DEFINITY®, or other echo contrast agent.
  • Prior SAE associated with perflutren, DEFINITY®, or administration of other echo contrast agent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,060 participants (actual)

Study arms

  • Other
    DEFINITY® (Perflutren Lipid Microsphere)

    Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography

    Drug: DEFINITY®

Interventions

  • DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert

    Also known as: DEFINITY, Perflutren Lipid Microsphere injectable suspension

06

What researchers measure

Primary outcomes

  1. The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration

    Time frame: during or within 30 minutes of administration

Secondary outcomes

  1. Serious Adverse Events

    Summary of the number and percentage of participants with serious adverse events occuring following completion of DEFINITY administration

    Time frame: Through 24 hours

  2. Adverse Events

    Summary of the number and percentage of participants with adverse events occuring following completion of DEFINITY administration

    Time frame: Through 24 hours

07

Results

Posted Jan 14, 2011

Participant flow

Participants were recruited from hospitals and clinics in the USA between February 2008 and April 2009

Participant flow — Overall Study
MilestoneDEFINITY®
Started1060
Completed1053
Not completed7
Withdrew: Withdrawal by subject1
Withdrew: No iv access5
Withdrew: Vsd1

Outcome measures

PrimaryThe Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration
Time frame:
during or within 30 minutes of administration
Reported as:
Number · Participants
The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration
ParticipantsDEFINITY®
The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration0
SecondarySerious Adverse Events

Summary of the number and percentage of participants with serious adverse events occuring following completion of DEFINITY administration

Time frame:
Through 24 hours
Reported as:
Number · Participants
Serious Adverse Events
ParticipantsDEFINITY®
Serious Adverse Events0
SecondaryAdverse Events

Summary of the number and percentage of participants with adverse events occuring following completion of DEFINITY administration

Time frame:
Through 24 hours
Reported as:
Number · Participants
Adverse Events
ParticipantsDEFINITY®
Adverse Events114

Adverse events

Collected over Through 24 hours post last dose. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DEFINITY®—0/1,053 (0%)35/1,053 (3.3%)
Most frequent other events
Most frequent other events
EventDEFINITY®
HeadacheNervous system disorders13/1053
NauseaGastrointestinal disorders9/1053
Back PainMusculoskeletal and connective tissue disorders7/1053
TremorNervous system disorders6/1053

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DEFINITY (Perflutren Lipid Microsphere)
<=18 years0
Between 18 and 65 years609
>=65 years444
Age, Continuous
Age, Continuous(years)DEFINITY (Perflutren Lipid Microsphere)
Mean61.3 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)DEFINITY (Perflutren Lipid Microsphere)
Female400
Male653
08

Study locations

16 sites
  • UCSD Medical Center
    San Diego, California 92103-8411, United States
  • Alfieri Cardiology
    Newark, Delaware 19713, United States
  • Northwestern University
    Chicago, Illinois 60611-2969, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Park Nicolett Institute
    Saint Louis Park, Minnesota 55426, United States
  • Cardiovascular Consultants, P.C.
    Kansas City, Missouri 64111, United States
  • St. Louis University
    Saint Louis, Missouri 63110, United States
  • St. Luke's-Roosevelt Hospital
    New York, New York 10025, United States
  • Mt Sinai Medical Center
    New York, New York 10029, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Meritcare Heart Center Cardiology
    Fargo, North Dakota 58122, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • York Hospital
    York, Pennsylvania 17405, United States
  • Consultants in Cardiology
    Fort Worth, Texas 76104, United States
  • University of Texas Medical Center
    Galveston, Texas 77555, United States
  • The Methodist DeBakey Heart Center
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2008
First posted
Feb 28, 2008
Start
Feb 2008
Primary completionActual
May 2009
CompletionActual
Jul 2009
Results first posted
Jan 14, 2011
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00625365
Responsible party
Sponsor
First posted
Feb 28, 2008
Start date
Feb 2008
Primary completion
May 2009
Completion
Jul 2009
Results posted
Jan 14, 2011
Last update
Nov 24, 2020

Study contacts

Veronica Lee, MD
study director · Lantheus Medical Imaging

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion